NDT Advance Access published online on July 26, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi010
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Renal Medicine, Singapore General Hospital, Outram Road, Singapore 168751
* To whom correspondence should be addressed. Background. Peritonitis and exit-site infections (ESI) are major causes of morbidity in peritoneal dialysis (PD) patients. The application of topical mupirocin to exit sites reduces such complications, and prolongs life in PD. Since the year 2000, this topical treatment has been used in our hospital on new PD patients. We analysed the results of this protocol, and studied the effects of comorbidities on the incidence of peritonitis. Methods. We studied 740 incident PD patients, who were divided into two groups based on year of entry into PD (Group 1 from January 1998 to December 1999 inclusive, topical mupirocin not used, and Group 2 from January 2000 to March 2004 inclusive, topical mupirocin used). The variables we studied included gender, age, diabetic status, ischaemic heart disease, peripheral vascular disease, cerebrovascular disease and serum albumin. Results. The application of topical mupirocin at the exit site led to a significant reduction in the rate of peritonitis (0.443 vs 0.339 episodes per patient-year; P<0.0005) and in ESI (0.168 vs 0.156 episodes per patient-year; P<0.005), results attributed primarily by the significant (P<0.005) reduction in Staphylococcus aureus infection. There was also an unexpected lowering of Pseudomonas aeruginosa peritonitis in the mupirocin group (P<0.005). Stepwise multiple logistic regression analysis revealed that only the application of mupirocin and serum albumin levels were significant predictors of peritonitis. Conclusions. Our study, although retrospective, has demonstrated that the topical use of mupirocin was associated with a significant reduction in ESI and peritonitis and, unexpectedly, with findings of fewer incidences of Pseudomonas peritonitis. Serum albumin level before the initiation of PD was a strong predictor of subsequent peritonitis. Mupirocin, with its low toxicity, ease of application and demonstrable beneficial effect in reducing ESI and peritonitis is now used on all of our incident PD patients.
Received October 10, 2004
Accepted April 5, 2005
Original Articles
The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital
Christopher Thiam-Seong Lim, E-mail: grmlts{at}sgh.com.sg
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Aslam, J. Bernardini, L. Fried, R. Burr, and B. Piraino Comparison of Infectious Complications between Incident Hemodialysis and Peritoneal Dialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1226 - 1233. [Abstract] [Full Text] [PDF]
|
|